Imunon reports Q1 EPS (28c), consensus (36c)

“IMUNON (IMNN) continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer. In 2024, our Phase 1/2 OVATION 2 Study delivered groundbreaking data, demonstrating that IMNN-001 is the first immunotherapy to extend both progression-free and overall survival in women newly diagnosed with ovarian cancer when combined with chemotherapy, and we continue to report promising results from the trial further supporting our therapeutic approach, including new translational and safety data this past quarter based on ongoing analyses,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “We look forward to building on this data and momentum, with a strong first quarter in 2025. The initiation of the first trial site for our Phase 3 OVATION 3 pivotal study marks a critical step toward our goal of delivering a new frontline treatment for women with limited options and urgent unmet medical needs. The acceptance of our OVATION 2 results for an oral presentation at ASCO also underscores the scientific community’s recognition of IMNN-001’s potential. These milestones reflect the strength of our clinical program, the dedication of trial investigators and patients, and our productive engagement with the FDA to finalize our Phase 3 study design. As we advance this historic opportunity, IMUNON remains committed to bringing safe, effective therapies to women battling ovarian cancer,” Dr. Lindborg continued.